Key sunitinib‐related biomarkers for renal cell carcinoma

Key sunitinib‐related biomarkers for renal cell carcinoma

Abstract Background Renal cell carcinoma (RCC) contributed to 403,262 new cases worldwide in 2018, which constitutes 2.2% of global cancer, nevertheless, sunitinib, one of the major targeted therapeutic agent for RCC, often developed invalid due to resistance. Emerging evidences suggested sunitinib...

Full description

Bibliographic Details
Main Authors:	Yun Peng, Shiqiang Dong, Yuxuan Song, Dingkun Hou, Lili Wang, Bowen Li, Haitao Wang
Format:	Article
Language:	English
Published:	Wiley 2021-10-01
Series:	Cancer Medicine
Subjects:	CEACAM4 CRYBB1 HAMP renal cell carcinoma sunitinib
Online Access:	https://doi.org/10.1002/cam4.4206

Similar Items

Sunitinib resistance in renal cell carcinoma
by: Christudas Morais
Published: (2014-04-01)

Acute Acalculous Cholecystitis Associated with Sunitinib Treatment for Renal Cell Carcinoma
by: Se Woong Choi, et al.
Published: (2020-02-01)

Metabolomic Analysis to Elucidate Mechanisms of Sunitinib Resistance in Renal Cell Carcinoma
by: Tomonori Sato, et al.
Published: (2021-12-01)

Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
by: Shibasaki, Noboru
Published: (2016)

Complete remission of metastatic renal cell carcinoma to the bone with sunitinib
by: Akihiro Yoshimura, et al.
Published: (2020-09-01)

Activity and safety of sunitinib in poor risk metastatic renal cell carcinoma patients
by: Romualdo Barroso-Sousa, et al.
Published: (2014-12-01)

HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma
by: Maroto P, et al.
Published: (2017-09-01)

Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial
by: Jun Guo, et al.
Published: (2018-05-01)

Metastatic Renal Cell Carcinoma: Sunitinib as First-Line Treatment; Results of a Retrospective Study
by: El-Hadaad Hend Ahmed, et al.
Published: (2015-12-01)

Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies
by: Xinan Sheng, et al.
Published: (2020-03-01)

Novel mutations in CRYBB1/CRYBB2 identified by targeted exome sequencing in Chinese families with congenital cataract
by: Peng Chen, et al.
Published: (2018-10-01)

Sunitinib in Metastatic Renal Cell Carcinoma: The Pharmacological Basis of the Alternative 2/1 Schedule
by: Antonello Di Paolo, et al.
Published: (2017-08-01)

Long Non-coding RNA CCAT1 Acts as an Oncogene and Promotes Sunitinib Resistance in Renal Cell Carcinoma
by: Liping Shan, et al.
Published: (2020-09-01)

Case report of a renal cell carcinoma patient with acute pancreatitis under both sunitinib and axitinib treatment
by: Utku Oflazoglu, et al.
Published: (2016-08-01)

Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib
by: Fiala O, et al.
Published: (2021-05-01)

Characterisation of the Morphological, Functional and Molecular Changes in Sunitinib-Resistant Renal Cell Carcinoma Cells
by: Hossam Kamli, et al.
Published: (2018-08-01)

Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma
by: Wen Cai, et al.
Published: (2017-08-01)

Clinical and Pathological Complete Remission in a Patient With Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: Is mRCC Curable With Targeted Therapy?
by: Amishi Y. Shah, et al.
Published: (2015-03-01)

Long-term benefit of sunitinib in patients with metastatic renal cell carcinoma in Latin America: retrospective analysis of patient clinical characteristics
by: Smaletz O, et al.
Published: (2016-11-01)

Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients
by: Çetin Ordu, et al.
Published: (2016-06-01)

Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment
by: Nanna Bæk Møller, et al.
Published: (2019-09-01)

Encephalic Leukocytoclastic Vasculitis during Treatment with Sunitinib for Renal Cell Carcinoma: A Case Report
by: Maria Massucci, et al.
Published: (2021-01-01)

Metastatic collecting duct carcinoma of the kidney treated with sunitinib
by: M'rabti Hind, et al.
Published: (2011-07-01)

Efficacy and Safety of Individualized Schedule of Sunitinib by Drug Monitoring in Patients with Metastatic Renal Cell Carcinoma
by: Zhu X, et al.
Published: (2021-08-01)

Sunitinib Enables a Clinical and Pathological Complete Remission of Metastatic Renal Cell Carcinoma (mRCC)
by: Bo Peng, et al.
Published: (2017-05-01)

Practical recommendations for the prevention and correction of adverse reactions of sunitinib
by: S. L. Gutorov, et al.
Published: (2014-07-01)

Practical recommendations for the prevention and correction of adverse reactions of sunitinib
by: S. L. Gutorov, et al.
Published: (2014-07-01)

Comparative Efficacy, Safety, and Costs of Sorafenib vs. Sunitinib as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
by: Huan Deng, et al.
Published: (2019-06-01)

Brazilian data of renal cell carcinoma in a public university hospital
by: Pedro Aguiar Junior, et al.
Published: (2016-02-01)

Meta-Analysis of ABCG2 and ABCB1 Polymorphisms With Sunitinib-Induced Toxicity and Efficacy in Renal Cell Carcinoma
by: Fengjun Sun, et al.
Published: (2021-03-01)

Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis
by: Huan Deng, et al.
Published: (2019-05-01)

Molecular and Functional Analysis of Sunitinib-Resistance Induction in Human Renal Cell Carcinoma Cells
by: Magdalena Rausch, et al.
Published: (2021-06-01)

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
by: Asim Amin, et al.
Published: (2018-10-01)

When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report
by: Yassir Sbitti, et al.
Published: (2018-03-01)

An Unusual Metastatic Renal Cell Carcinoma with Maintained Complete Response to Sunitinib Treatment
by: Luis Chara, et al.
Published: (2011-12-01)

Gallbladder Metastasis from Renal Cell Carcinoma
by: Takashi Kawahara, et al.
Published: (2010-01-01)

Visceral Adiposity as a Significant Predictor of Sunitinib-Induced Dose-Limiting Toxicities and Survival in Patients with Metastatic Clear Cell Renal Cell Carcinoma
by: Jee Soo Park, et al.
Published: (2020-12-01)

Identification of MX2 as a Novel Prognostic Biomarker for Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
by: Yuang Wei, et al.
Published: (2021-07-01)

A 2/1 Sunitinib Dosing Schedule Provides Superior Antitumor Effectiveness and Less Toxicity Than a 4/2 Schedule for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
by: Huan Deng, et al.
Published: (2020-03-01)

Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma
by: Caroline Randrup Hansen, et al.
Published: (2017-02-01)